RxDoctor Payments Data

Jessica Bailey, APRN

Primary Care · Somerset, KYNPI 1427790039

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 29.4% of the total.

$539in general payments, 2019–2025

Across 33 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$158
  • Pfizer$143
  • Novartis$90
  • Kestra Medical Technology Services, Inc.$45
  • Bayer$35
  • AstraZeneca$33
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$539100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$539 in reported general payments places this provider in the 60th percentile of 80 primary care providers in Kentucky.

See all primary care providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,844
Medicare patients
57
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$12,664
RexultiBrexpiprazole17$10,940
JanuviaSitagliptin Phosphate25$6,909
FarxigaDapagliflozin Propanediol17$4,972
Divalproex Sodium38$3,852
Fiasp FlextouchInsulin Aspart (Niacinamide)21$3,617
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$3,328
Lubiprostone27$2,339
Olanzapine49$2,145
Gabapentin119$1,998
Levothyroxine Sodium70$1,226
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$1,217
Buspirone Hcl44$1,125
Humalog Kwikpen U-100Insulin Lispro25$1,037
Potassium Chloride63$1,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$12,66443 claims
MerckJanuvia$18$6,90925 claims
AstraZenecaFarxiga$33$4,97217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 80 primary care providers in Kentucky.

Other primary care in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →